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Background: Influenza virus infections are responsible for significant morbidity worldwide and therefore it remains
a high priority to develop more broadly protective vaccines. Adjuvation of current seasonal influenza vaccines has
the potential to achieve this goal.
Methods: To assess the immune potentiating properties of Matrix-M™, mice were immunized with virosomal
trivalent seasonal vaccine adjuvated with Matrix-M™. Serum samples were isolated to determine the hemagglutination
inhibiting (HAI) antibody titers against vaccine homologous and heterologous strains. Furthermore, we assess whether
adjuvation with Matrix-M™ broadens the protective efficacy of the virosomal trivalent seasonal vaccine against vaccine
homologous and heterologous influenza viruses.
Results: Matrix-M™ adjuvation enhanced HAI antibody titers and protection against vaccine homologous strains.
Interestingly, Matrix-M™ adjuvation also resulted in HAI antibody titers against heterologous influenza B strains, but
not against the tested influenza A strains. Even though the protection against heterologous influenza A was induced
by the adjuvated vaccine, in the absence of HAI titers the protection was accompanied by severe clinical scores and
body weight loss. In contrast, in the presence of heterologous HAI titers full protection against the heterologous
influenza B strain without any disease symptoms was obtained.
Conclusion: The results of this study emphasize the promising potential of a Matrix-M™-adjuvated seasonal trivalent
virosomal influenza vaccine. Adjuvation of trivalent virosomal vaccine does not only enhance homologous protection,
but in addition induces protection against heterologous strains and thus provides overall more potent and broad
protective immunity.
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Influenza virus infections cause significant morbidity and
mortality, with 5 million severely ill and 250 –500.000
deaths annually, in particular among the elderly, the
immunocompromised and people with chronic diseases.
The estimated global attack rate of influenza virus is 5 –
10 % for adults and 20 – 30 % for children, which causes
large health and economic burdens for the society [1].* Correspondence: Esaeland@its.jnj.com
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(http://creativecommons.org/publicdomain/zeCirculating seasonal influenza strains belong to A and B
viruses. Influenza A viruses are classified on the basis of
the antigenic properties of their hemagglutinin (HA) and
neuraminidase (NA) glycoproteins. To date, 18 HA
subtypes and 9 NA subtypes have been identified [2].
Influenza B viruses are classified in two lineages, B/Yama-
gata and B/Victoria [3]. While the host range of influenza
B viruses is limited to humans and seals [4], influenza A
viruses infect a broad range of hosts including humans,
birds and pigs [5]. There is a constant threat of influenza
A viruses crossing the species barrier and causing serious
disease burden in humans [6], as was recently demon-
strated by human cases of avian H7N9 in China [7].distributed under the terms of the Creative Commons Attribution 4.0
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designed to elicit protective immunity against two specific
influenza A strains (H1N1 and H3N2) and one B strain.
The vaccines are mainly based on HA and primarily induce
antibodies directed to the receptor binding site located on
the globular head of the HA molecule which prevent the
interaction of the virus with host cells and thereby block
viral entry. However, since the globular head of the HA is
highly variable [8, 9] seasonal vaccines require annual
updating to be effective. Each year the World Health
Organization provides recommendations for the compos-
ition of seasonal influenza vaccines, based on predictions
of the strains that will become dominant in the upcoming
season. These predictions are based on global monitoring
of the circulating H1N1, H3N2 and B strains, but this pro-
cedure is an error-prone process and mismatches between
circulating virus and vaccine strains occur frequently. A
particular challenge is posed by the fact that two B-strains
(one from each lineage) are co-circulating. In the last dec-
ade, the dominant strain was correctly predicted in only
50 % of the cases [10, 11].
Despite influenza strain variability, the HA contains
conserved epitopes that may be targeted by vaccination
[12–15]. For the development of a broadly protective in-
fluenza vaccine that protects against mismatched seasonal
strains and potential pandemic strains it may be beneficial
to redirect the immune response towards such conserved
epitopes.
A possible approach to this may be the use of adju-
vants. It has been shown previously that adjuvants, such
as MF59, the AS03 adjuvant system and saponin-based
adjuvants have an ability to enhance and broaden the
immune response elicited by vaccination [16–26].Fig. 1 Matrix-M™ enhances homologous HAI responses induced by TVV.
per strain or TVV + MM (+). Three weeks later, serum samples were obtain
A/California/07/09, H3N2 A/Perth/16/09 (A/Victoria/210/09-like), and B/Bri
transformed titers. (*p < 0.05, **p < 0.01, ***p < 0.001, compared to the ve
multiple comparisons). Results of the statistical comparisons between on
TVV + MM are summarized in Additional file 1: Table S1Here we evaluated the ability of a seasonal trivalent
virosomal vaccine (TVV) adjuvated with the saponin-
based adjuvant Matrix-M™ [27, 28] to elicit heterologous
hemagglutination inhibiting (HAI) antibodies and protec-
tion in mice. HAI antibodies are very potent at preventing
the entry of influenza virus into the cell, through blocking
the interaction between the HA head and cellular sialic
acid receptors, and in this way fully prevent infection
[29, 30]. Furthermore, the HAI titer is the only accepted
correlate of protection for influenza vaccines [31].
We demonstrate that Matrix-M™-adjuvated TVV im-
proves homologous HAI titers and protection. In addition,
Matrix-M™-adjuvated TVV elicits heterologous HAI titers
against influenza B, but not against influenza A, and provides
protection against heterologous influenza strains in mice.
Results
Matrix-M™-adjuvated TVV elicits high homologous HAI
and protection
To investigate whether Matrix-M™ can enhance the overall
humoral immune responses after immunization with TVV,
we first evaluated vaccine homologous HAI responses in
mice against all three vaccine strains: H1N1, H3N2 and B.
A single immunization with a trivalent virosomal vaccine
(TVV) alone did not result in HAI responses against the
vaccine homologous H1N1 A/California/07/09 (non-signifi-
cant compared to PBS, p = 1). Adjuvation with Matrix-M™
significantly enhanced the responses (p = 0.014 compared
to 1xTVV), to a level comparable to a prime-boost
immunization with TVV alone. A second immunization
with Matrix-M™-adjuvated TVV (TVV+MM) further sig-
nificantly improved the HAI titers (p = 0.003 compared to
1xTVV+MM, Fig. 1, left panel, Additional file 1: Table S1).Mice (n = 8/group) were immunized with TVV (−) containing 3μg HA
ed and tested for HAI responses against vaccine homologous H1N1
sbane/60/08 (B/Victoria lineage). Black bars indicate medians of log2
hicle control group (PBS) using Wilcoxon’s rank-sum test adjusted for
e and two immunizations and between immunizations with TVV and
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significant higher HAI titers against H3N2 A/Perth/16/
09 (a strain that shows 98.8 % amino acid homology
with the HA of the vaccine strain A/Victoria/210/09,
Additional file 5: Figure S4) compared to PBS (p < 0.001)
and adjuvation with Matrix-M™ further improved these
responses (p < 0.001 compared to 1xTVV). Prime-boost
immunization with TVV or TVV +MM did not further
significantly enhance the HAI response as compared to
single immunizations (p = 0.143 and p = 0.448, respectively,
Fig. 1, middle panel).
A pattern similar to that of the HAI response against
vaccine homologous H1N1 was observed for HAI re-
sponses against the B strain, where one immunization
with TVV +MM induced HAI titers against the vaccine
homologous B/Brisbane/60/08 strain (p < 0.001 compared
to PBS), and up to the level comparable to prime-boost
immunization with TVV alone. A second immunization
with TVV +MM significantly boosted the primary HAI
responses (p < 0.001 compared to 1xTVV +MM) (Fig. 1,
right panel).
Next we determined whether the enhanced homologous
HAI titers obtained after Matrix-M™ adjuvation of TVV
were associated with enhanced homologous protection.
Therefore, mice were immunized with various suboptimal
protective vaccine doses (suboptimal TVV doses were de-
termined in a separate experiment, data not shown) with
or without the addition of Matrix-M™ followed by intrana-
sal challenge with vaccine homologous strains H1N1 A/
Netherlands/602/09, H3N2 A/Perth/16/09 or B/Malaysia/
2506/04 (B/Victoria lineage) (sequence alignments in
Additional file 4: Figure S3, Additional file 5: Figure S4,
Additional file 6: Figure S5). The results demonstrate that
adjuvation with Matrix-M™ significantly improved TVV-
induced protection against all three vaccine homologous
strains as compared to TVV alone. (p = 0.026, p < 0.001
and P < 0.001 in an across doses comparison for the hom-
ologous H1N1, H3N2 and B challenges respectively) (Fig. 2
and Additional file 2: Figure S1).
Matrix-M™-adjuvated TVV induces HAI responses against
heterologous influenza B, but not against influenza A
strains
In order to determine the breadth of the response, we
analyzed HAI responses induced by TVV and TVV +
MM against the heterologous influenza strains H1N1 A/
Brisbane/59/07, H3N2 A/Hong Kong/1/68 and B/Florida/
04/06 (B/Yamagata lineage). To compellingly assess the
breadth of the response of TVV +MM we selected strains
that show the highest difference possible in HA homology
compared to the corresponding subtypes in the vaccine
(the homology between the vaccine and challenge strains
is depicted in Fig. 3b and Additional file 4: Figure S3,
Additional file 5: Figure S4, Additional file 6: Figure S5).HAI titers against heterologous H1N1 and H3N2 strains
were not detected after 1 or 2 immunizations with TVV
or TVV +MM (Fig. 3a). Furthermore, no HAI responses
were detected against B/Florida/04/06 after one or two
immunizations with TVV. In contrast, after a single
immunization with TVV +MM, HAI titers were detected
in 4 out of 8 mice, although the overall group response
was not statistically significant (p = 0.154 compared to
PBS). The HAI response to the heterologous B strain was
increased after a second immunization with TVV +MM
(p = 0.003 compared to PBS) (Fig. 3a). We tested a second
strain of the B/Yamagata (B/Massachussets/01/12) lineage
and found also for this strain comparable levels of HAI
responses (Additional file 3: Figure S2B). These results
demonstrate that adjuvation of TVV leads to induction of
cross-reactive HAI against the two tested heterologous B
strains but not against the two heterologous A strains.
Matrix-M™-adjuvated TVV elicits protection against
heterologous influenza strains
To investigate whether adjuvation of TVV with Matrix-M™
improves protection against heterologous strains, mice
were immunized with a single dose of TVV or TVV +
MM (corresponding to 3μg of each HA as was used in
previous studies [32]). Four weeks later, mice were chal-
lenged with vaccine-heterologous wild-type derived mouse
adapted H1N1, H3N2, or influenza B virus (see Fig. 3b,
and sequence alignment Additional file 4: Figure S3,
Additional file 5: Figure S4, Additional file 6: Figure S5),
and monitored for 21 days for survival, body weight (Fig. 4)
and clinical signs (Additional file 3: Figure S2A).
Despite the absence of detectable HAI titers against
heterologous influenza A, Matrix-M™-adjuvated TVV was
able to provide significant protection against mortality after
heterologous challenge with H1N1 (A/Brisbane/59/07) and
H3N2 (A/Hong Kong/1/68) strains while immunizations of
non-adjuvated vaccine did not protect the animals against
weight loss and clinical signs or mortality (Fig. 4). Although
80 % (H1N1) and 100 % (H3N2) of animals survived
the challenge (p = 0.001 and p < 0.001 compared to PBS, re-
spectively), they transiently lost substantial body weight and
experienced severe clinical symptoms, indicating that
this protection was not complete. However body weight
loss (p = 0.015 and p = 0.001 respectively) and clinical
scores (p < 0.001 and p < 0.001, respectively) were sig-
nificantly lower compared to PBS.
We also investigated whether the enhanced cross-
reactive HAI response translated into enhanced protection
against vaccine heterologous B/Florida/04/06 (B/Yamagata
lineage). A single immunization with TVV alone protected
only 3 out of 10 mice, which was not statistically significant
(p = 0.412 compared to PBS). The mice lost substantial
body weight during the study period (p = 1 compared
to PBS) and exhibited severe disease symptoms (p = 1

































































































Fig. 2 Survival proportion of homologous challenged mice. Mice (6 or 10/group) were immunized once with different doses of seasonal trivalent
virosomal influenza vaccine (TVV) with or without Matrix-M™ or PBS and challenged with vaccine-homologous virus strains H1N1 A/Netherlands/
602/09, H3N1 A/Perth/16/09 or B/Malaysia/2506/04 and monitored for 21 days for survival, body weight loss and clinical symptoms (Additional file
2: Figure S1). Graphs represent Kaplan-Meier survival curves. The HA amino acid sequences of H1N1 A/Netherlands/602/09 and H1N1 A/California/
07/09 differ by 5 residues (99.5 % homology), those of H3N2 A/Perth/16/09 and H3N2 A/Victoria/210/09 differ by 7 residues (98.8 % homology),
and those of B/Malaysia/2506/04 and B/Brisbane/60/08 differ by 5 residues (99.2 % homology) (Additional file 4: Figure S3, Additional file 5: Figure S4,
Additional file 6: Figure S5)
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MM resulted in full protection (p < 0.001 compared to
PBS) with hardly any body weight loss (p < 0.001 compared
to PBS) and no clinical signs (p < 0.001 compared to PBS)
after challenge with the heterologous influenza B strain
(Fig. 4).
Discussion
Influenza vaccines need to be annually updated to effi-
ciently protect against circulating strains. Therefore, it re-
mains a high priority to establish broad reactive immunity
against influenza by vaccination. An attractive approachmay be to attempt redirecting the immune response
towards the conserved epitopes on the viral antigens
by adjuvated seasonal influenza vaccines.
It has previously been demonstrated that adjuvants
can enhance and broaden immune responses of seasonal
and pandemic vaccines in animal models and in humans
[16–24]. For example, MF59 (squalene oil-in-water emul-
sion [33] has been shown to enhance vaccine-elicited
humoral immune responses in animals [20, 34, 35] and in
humans [35–39] and it is currently licensed for use in
combination with a seasonal influenza vaccine (Fluad®).
Fluad and an MF59 adjuvated H5N1 pandemic vaccine
Fig. 3 The addition of Matrix-M™ induces HAI responses against a heterologous influenza B strain but not against heterologous H1N1 and H3N2
strains. a Mice (n = 7-8/group) were immunized with TVV (−) containing 3μg HA per strain or TVV + MM (+). Three weeks later, serum samples
were obtained and tested for HAI responses against H1N1 A/Brisbane/59/07 and H3N2 A/Hong Kong/1/68 and B/Florida/04/06 (B/Yamagata
lineage). Black bars indicate medians of log2 transformed titers (*p < 0.05, **p < 0.01, ***p < 0.001 compared to the vehicle control group (PBS)
using Wilcoxon’s rank-sum test adjusted for multiple comparisons). Comparisons between one and two immunizations and between immunizations
with TVV and TVV +MM are summarized in Additional file 1: Table S1. b Numbers indicate HA homology as percentages of amino acid similarity
(difference indicated in red) of the HA head region and of the whole HA sequence between vaccine strains and the assay virus strains (alignment of full
length HA’s in Additional file 4: Figure S3, Additional file 5: Figure S4, Additional file 6: Figure S5). H1/Cal = A/California/07/09. H1/Bris = A/Brisbane/59/
07. H3/Vic = A/Victoria/210/09. H3/HK = A/Hong Kong/1/68. B/Bris = B/Brisbane/60/08. B/Florida = B/Florida/04/06
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HAI responses in ferrets [20] and in humans [16, 17,
36, 39], respectively. In adults, cross-reactive HAI re-
sponses were also detected against drifted H3N2 influenza
viruses [36]. MF59-adjuvated TIV also elicited some cross-
reactive HAI responses against heterologous influenza B
viruses in adults [37] but not in unprimed children [39].
Another adjuvant licensed for human use in combin-
ation with an H1N1 pandemic vaccine (Pandemrix®) is the
AS03 adjuvant system (α-tocopherol and squalene in an
oil-in-water emulsion [40]). It has been demonstrated, in
pre-clinical and clinical studies, that the AS03-adjuvated
H5N1 pandemic vaccines can elicit H5 cross-reactive HAI
responses which correlated to protection [18, 19, 41].In our studies, we have used Matrix-M™, an adjuvant
that consists of a mixture of two purified and well char-
acterized saponin fractions (Matrix-A and Matrix-C)
[27]. Compared to the original formulation that con-
tained non-fractionated Quillaja saponins together with
viral antigens in a single particle [25], the individual par-
ticle formulation improves both adjuvant activity and the
safety profile in humans [21]. Matrix-M™ in combination
with TVV has been shown to enhance antibody and cellular
immune responses against influenza in mice [22] and
humans (Clinical-Trials.gov NCT01444482). Matrix-M™-
adjuvated virosomal H9N2 and H5N1 vaccines have been
evaluated in pre-clinical and clinical studies [21, 23, 42–45].
Mice immunized with an experimental H9N2 virosomal

























































































































Fig. 4 Matrix-M™ adjuvated TVV enhances protection against heterologous H1N1 H3N2 and influenza B strains. Mice (n = 10/group) were
immunized once with TVV (containing 3μg HA per strain) with or without Matrix-M™. Four weeks later, mice were challenged with 25xLD50
of mouse-adapted heterologous H1N1 A/Brisbane/59/07, H3N2 A/Hong Kong/01/68 or B/Florida/04/06 and monitored for 21 days for
survival, body weight loss (clinical symptoms, Additional file 3: Figure S2A). Graphs represent the Kaplan-Meier survival curves (left) and
mean body weight change with 95 % confidence interval (right). Asterisks indicate statistically significant differences from the vehicle
control group (*p < 0.05, ** p < 0.01, ***p < 0.001, according to the materials and methods section)
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In addition, cross-clade H5 HAI responses were observed
in mice that received a Matrix-M™-adjuvated H5N1
candidate vaccine compared to non-adjuvated H5N1
candidate pandemic vaccine in mice [23]. These findings
were later confirmed in humans [21, 43].
Most studies concerning adjuvated influenza vaccines
demonstrate cross-reactive responses against strains that
are closely related to the vaccine strain.
Recently, we have shown that mice immunized twice
with TVV +MM were protected from death after H5N1
and H7N7 challenge. Ferrets were partially protected
against H5N1, but not against H7N9 after two immuni-
zations with TVV +MM [26].
In our study the H1N1 and H3N2 challenge strains only
show 87 % and 80 % homology (based on HA protein
sequence) with the corresponding vaccine strains andyet a single immunization with TVV +MM could protect
mice against these influenza A strains.
The HA among influenza B strains is more conserved
compared to influenza A (>91 % based on HA protein
sequence as determined by alignment of the circulating
strains from 1970 to 2008, data not shown). Nonetheless,
the current TIV formulations are inadequate to elicit pro-
tection against both influenza B lineages, particularly in
naïve individuals [46, 47]. In addition, due to regular co-
circulation of the strains from both lineages of influenza
B, it is particularly difficult to predict which influenza B
virus will be the dominant one in the upcoming season.
The frequent mismatch between the influenza B lineage
selected for seasonal vaccine and the dominant circulating
B lineage results in the poor efficacy of seasonal vaccines
against B strains [10]. One solution to improve vaccine ef-
ficacy against B strains is the inclusion of strains from
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quadrivalent influenza vaccine (QIV). An alternative ap-
proach may be the enhancement and broadening of the
vaccine-elicited immune response by an adjuvant such as
Matrix-M™. Our results demonstrate that a Matrix-M™
adjuvated seasonal trivalent virosomal vaccine elicits HAI
titers not only against vaccine homologous B/Brisbane/60/
08 but also against the vaccine mismatched B/Florida/04/
06 and B/Massachusetts/02/12 (93 % homology with the
vaccine strain for both) In addition to the enhanced pro-
tection against the vaccine matched B strain, full protec-
tion against a lethal challenge with the B/Florida/04/06
strain was achieved.
In contrast to influenza B, Matrix-M™-adjuvated TVV
did not elicit cross-reactive HAI responses against heter-
ologous H1N1 or H3N2 influenza A strains. The lack of
cross-reactive influenza A HAI response is in agreement
with our previous study [26] and with studies that use a
monovalent H1N1 split influenza vaccine formulated as
ISCOMs [24, 48].
The presence of cross-reactive influenza B HAI and
the absence of cross-reactive influenza A HAI can be ex-
plained by the higher homology between the HA head of
the two B lineages, as compared to the homology for
H1N1 and H3N2 strains (Fig. 3b and Additional file 2:
Figure S1, Additional file 3: Figure S2, Additional file 4:
Figure S3). Similarly, cross-reactive HAI responses to
relatively more closely related H5N1 strains were shown to
be induced in mice immunized with a Matrix-M™-adjuvated
virosomal H5N1 vaccine (98.7 % and 96.5 % HA homology
of the NIBRG-88 and IBCDCRG-6 strains compared to the
NIBRG-14 vaccine strain, respectively) [23].
Considering that Matrix-M™-adjuvated TVV elicited
HAI titers against two heterologous influenza B strains
and provided full protection against challenge with the
heterologous B/Florida/04/06, it is conceivable that HAI
antibodies played a key role in protection, but does
not exclude the contribution of other immunological
mechanisms. Interestingly, despite the absence of HAI
titers against the two heterologous influenza A strains,
adjuvation with Matrix-M™ significantly improved TVV-
induced protection against the heterologous H1N1
and H3N2 strains. In contrast to protection against
heterologous influenza B, protection against influenza
A was accompanied by the severe weight loss and disease
symptoms. It is conceivable that the mechanism of heter-
ologous protection induced by Matrix-M™-adjuvated TVV
differs between influenza A and influenza B. We suggest
that cross-reactive HAI antibodies play a key role in
the protection against B/Florida/04/06. In the absence
of cross-reactive HAI titers, as is the case for the two
tested influenza A strains, other protective mechanisms are
likely to play a key role. These include neutralization medi-
ated by HA stem-binding antibodies [12–14], antibodydependent cellular cytotoxicity (ADCC) [24, 48–50], or
T-cell mediated killing [24, 48, 51, 52]. The exact mechan-
ism of protection against heterologous influenza A strains
induced by Matrix-M™-adjuvated TVV remains to be
identified.
Conclusion
The results of this study together with our previous
results [26] emphasize the promising potential of a
Matrix-M™-adjuvated seasonal trivalent virosomal influenza
vaccine. Adjuvation of trivalent virosomal vaccine does not
only enhance homologous protection, but in addition in-
duces protection against heterologous strains and thus pro-
vides overall more potent and broad protective immunity.
Materials and methods
Statement of ethics
All mouse and ferret experiments were performed in ac-
cordance with Dutch legislation on animal experiments
and approved by the DEC Consult (Independent ethical
institutional review board).
Immunization
Six-to eight-week-old female BALB/c (H-2d) mice (spe-
cific pathogen-free) were purchased from Charles River
(France). H1N1 A/California/07/09, H3N2 A/Victoria/
210/09 and B/Brisbane/60/08 monovalent virosomes were
prepared by Crucell (Berne, Switzerland) using conven-
tional procedures [53]. The monovalent virosomes were
mixed to obtain a trivalent virosomal vaccine (TVV).
Matrix-M™ (MM, 10μg/dose, Novavax AB, Uppsala,
Sweden) was mixed with TVV (at various doses, as in-
dicated) before immunization (TVV +MM). Mice were
immunized intramuscularly (i.m.) 1 to 3-times with
TVV or TVV +MM 3 weeks apart with 100μl vaccine
(50 μl per hind leg). Control groups received 100 μl
PBS. Three weeks after the final immunization blood was
collected to assess serum HAI responses (data shown for
1x and 2x immunization only). In the challenge experi-
ments mice received mouse adapted influenza virus four
weeks after the final immunization (data shown for 1x
immunization only).
Hemagglutination Inhibition (HAI) assay
HAI assays were performed as described before [45].
Briefly, sera were pre-absorbed with 0.5 % turkey red
blood cells (bioTRADING Benelux B.V., Mijdrecht, the
Netherlands) in PBS for 2 h. After removal by centrifuga-
tion, sera were treated for 16 h with receptor-destroying
enzyme (Sigma-Aldrich; St. Louis, MO, USA; diluted 1:25
in PBS) The receptor-destroying enzyme was heat inacti-
vated for 30 min at 56°C. Two-fold serial dilutions of the
sera (initial dilution 1:8) were incubated for 1 h at room
temperature with influenza virus (H1N1 A/California/07/
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H3N2 A/Perth/16/09, H3N2 A/Hong Kong/1/68, B/
Brisbane/60/08 reassortant (NYMC BX-35), B/Florida/
04/06, and B/Massachusetts/02/12) (see HA sequence
alignment in Additional file 4: Figure S3, Additional file
5: Figure S4, Additional file 6: Figure S5) standardized
to 8 hemagglutination units. Turkey red blood cells were
added and incubated for 60 min before hemagglutination
inhibition was determined. Each serum sample was tested
in duplicate. Titers were expressed as the reciprocal of the
highest dilution where complete agglutination inhibition
was observed.
Influenza challenge
Four weeks after the final immunization mice were anes-
thetized by intraperitoneal (i.p.) administration of 100 mg/
kg ketamine (Nimatek® 100 mg/ml, Eurovet, Cuijk, the
Netherlands) in combination with 20mg/kg xylazine
(Sedamun® 20 mg/ml, Eurovet). Mice were challenged
with 25xLD50 of (i) H1N1 A/Netherlands/602/09 or
mouse-adapted H1N1 A/Brisbane/59/07 or B/Florida/04/
06 (performed at Janssen Research and Development,
Leiden, the Netherlands) or (ii) mouse-adapted H3N2
A/Perth/16/09, H3N2 A/Hong Kong/1/68 or B/Malaysia/
2506/04 (performed at TNO Triskelion, Zeist, the
Netherlands) (HA sequence alignment see Additional file
4: Figure S3, Additional file 5: Figure S4, Additional file 6:
Figure S5) via the intranasal route (a total of 50μl, 25μl per
nostril). Notably, all challenge strains were wild-type or
wild-type derived and did not contain any PR8 derived
segments.
After challenge, mice were monitored for weight-loss,
clinical score and survival for 21 days or until humane
endpoint. Clinical scores for challenges performed at
Janssen Research and Development (i) were defined as:
0 = no clinical signs, 1 = rough coat, 2 = rough coat, less
reactive, passive during handling, 3 = rough coat, rolled
up, labored breathing, passive during handling, 4 = rough
coat, rolled up, labored breathing, unresponsive (=humane
endpoint) or found dead (=score 4).
Clinical scores for challenges at TNO (ii) were defined
as 0 = no clinical signs, 1 = rough coat, 2 = rough coat,
labored respiration 3 = rough coat, labored respiration,
hunched posture and/or blepharospasm, 4 = rough coat,
labored respiration, hunched posture, blepharospasm,
lethargic and/or thin/dehydrated. Humane endpoint was
defined as clinical score 4 for more than 2 consecutive
days (=score 5) and found dead = score 5.
Statistical analysis
Statistical differences between immunizations with TVV
with or without Matrix-M™ relative to negative control
group receiving PBS were evaluated for HAI titers. Add-
itionally, the effect of two immunizations compared toone immunization and the effect of Matrix-M compared
to TVV alone were determined (Additional file 1: Table
S1). Data was log-transformed and comparisons between
groups were made using the Wilcoxon rank-sum test with
adjustment for multiple comparisons (2 fold Bonferroni
and for comparisons with PBS a stepwise approach testing
first 2x and then 1x vaccination).
In the challenge models the vaccine groups were com-
pared to the vehicle control group for survival proportion,
change in body weight and clinical scores. For survival pro-
portion after challenge, a Fisher’s exact test was performed.
For body weight loss and clinical score analysis, repeated
measurements in the challenge phase were summarized as
a single outcome per animal using an Area Under The
Curve (AUC) approach where missing values for animals
that died before day 21 were imputed with a last-
observation-carried-forward method. Body weight data
are expressed as the change relative to the day 0 meas-
urement. The AUC was then defined as the summation
of the area above and below the baseline. An ANOVA
on AUC’s was done with group as explanatory factor.
Clinical scores were summarized as AUC per mouse
and groups were compared using a generalized linear
model with a cumulative logit distribution to compare
area under the curves for ordinal variable.
For the vaccine homologous challenges, survival pro-
portion per dose was compared to the vehicle control
group using a 2-sided Fisher’s exact test. Across doses
TVV +MM was compared to TVV only in a logistic re-
gression model with log(dose) as covariable, adjuvant as
factor and their interaction.
Statistical analyses were performed using SAS version
9.2 (SAS Institute Inc. Cary, NC, USA) and SPSS version
20 (SPSS Inc., IL, USA). Statistical tests were conducted
two-sided at an overall significance level of α = 0.05.Additional files
Additional file 1: Table S1. Summary statistical analysis HAI assays.
(DOCX 17 kb)
Additional file 2: Figure S1. Body weight loss and clinical scores
following homologous challenges. Mice (6 or 10/group) were immunized
once with different doses of seasonal trivalent virosomal influenza
vaccine (TVV) with or without Matrix-M™ or PBS and challenged with
vaccine-homologous virus strains H1N1 A/Netherlands/602/09, H3N1 A/
Perth/16/09 or B/Malaysia/2506/04 and monitored for 21 days for survival,
body weight loss and clinical symptoms. Graphs represent mean
body weight changes with 95 % confidence interval and median clinical
scores with interquartile range. The HA amino acid sequences of H1N1 A/
Netherlands/602/09 and H1N1 A/California/07/09 differ by 5 residues (99.5
% homology), those of H3N2 A/Perth/16/09 and H3N2 A/Victoria/210/09
differ by 7 residues (98.8 % homology), and those of B/Malaysia/2506/04
and B/Brisbane/60/08 differ by 5 residues (99.2 % homology) (Additional
file 4: Figure S3, Additional file 5: Figure S4, Additional file 6: Figure S5).
(PDF 96 kb)
Additional file 3: Figure S2. Clinical scores of heterologous challenges.
A) Mice (n = 10/group) were immunized once with TVV (containing 3 μg
Cox et al. Virology Journal  (2015) 12:210 Page 9 of 10HA per strain) with or without Matrix-M. Four weeks later, mice were
challenged with 25xLD50 mouse-adapted heterologous H1N1 A/Brisbane/
59/07, H3N2 A/Hong Kong/01/68 or B/Florida/04/06 and monitored for
21 days for survival, body weight loss and clinical symptoms Graphs
represent median clinical scores with interquartile range. Asterisks indicate
significance compared to the vehicle control group (*p < 0.05, ** p < 0.01,
***p < 0.001, according to the materials and methods section). B) Cross-
reactive influenza B HAI titers induced upon TVV +MM immunization. Mice
(n = 7-8/group) were immunized once or twice with TVV (−) (3μg HA
per strain) or TVV + MM (+). Three weeks after the last immunization,
serum samples were obtained and tested for HAI responses against B/
Massachusetts/02/12 (B/Yamagata lineage). Black bars indicate medians
of log2 transformed titers (*p < 0.05, **p < 0.01, ***p < 0.001 compared
to the vehicle control group (PBS) using Wilcoxon’s rank-sum test adjusted for
multiple comparisons). Comparisons between one and two immunizations
and between immunizations with TVV and TVV +MM are summarized in
Additional file 1: Table S1. (PDF 108 kb)
Additional file 4: Figure S3. Alignment of H1N1 strains based on
hemagglutinin amino acid sequence. H1/Cal = A/California/07/09
[GenBank: ACP44189.1], H1/NL = A/Netherlands/602/09 [GenBank
:AGU92700], H1/Bris = A/Brisbane/59/07 [GenBank: ADE28750.1]. Blue bar
indicates head domain defined as Cys59 to Cys292. (PDF 146 kb)
Additional file 5: Figure S4. Alignment of H3N2 strains based on
hemagglutinin amino acid sequence. H3/Vic = A/Victoria/210/09
[GenBank: AFM72883.1], H3/Perth = A/Perth/16/09 [GenBank: ACS71642.1],
H3/HK = A/Hong Kong/1/68 [GenBank: ACU79871.1]. Blue bar indicated
head domain defined as Cys68 to Cys293. (PDF 146 kb)
Additional file 6: Figure S5. Alignment of B-strains based on
hemagglutinin amino acid sequence. B/Bris = B/Brisbane/60/08 [GenBank:
ACN29380.1], B/Mal = B/Malaysia/2506/04 [GenBank: ACR15732], B/Florida =
B/Florida/04/06 [GenBank: ACF54246.1], B/Mass = B/Massachusetts/02/12
[GenBank: AGL06036.1]. Blue bar indicates head domain defined as Asn58 to
Glu307. (PDF 156 kb)
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